A Phase 2, Long-Term Extension (LTE) Study with Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT)

Project: Research

Project Details

StatusActive
Effective start/end date19/10/21 → 18/10/26

Keywords

  • phase 2 study
  • randomised controlled trial (RCT)
  • lupus
  • treatment efficacy
  • treatment safety
  • systemic lupus erythematosus (SLE)